These pro-inflammatory cytokines activate various inflammatory pathways that interfere with the development of NAFLD [31], such as the inhibitor kappa B kinase beta/nuclear factor kappa B (IKK/NF-kB) pathway and the c-Jun N-terminal kinase/activator protein 1 (JNK/AP1) pathway [32,33]. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.